Kymera reported Phase Ib biomarker activity for an oral STAT6 degrader and separately disclosed Phase 1b BroADen results for KT‑621, an oral pill for atopic dermatitis, that produced a mean 63% reduction in EASI scores. The biotech and analysts described the degrader’s biology as producing 'biologic‑like' biomarker changes and the pill’s rapid clinical signal as competitive with injectable standards. KT‑621 data came from a small cohort but showed an efficacy signal comparable to marketed anti‑IL‑4/13 antibodies; Kymera framed the oral approach as a potential, more convenient alternative. The degrader program’s Phase Ib biomarker readout sent investor attention to targeted protein degradation in immunology as a potential modality shift. Both readouts will force head‑to‑head planning and shape partnership or commercialization strategies if larger trials confirm tolerability and durability.